Short answer
TREACE MEDICAL CONCEPTS, INC. (TMCI) filed its Q3 2025 10-Q quarterly report on Nov 6, 2025 for the quarter ended Sep 30, 2025. Quarterly revenue was $50M (up 11.4% year over year) with net income of −$16M.
Q3 2025 key financials · XBRL
- Revenue
- $50M
- +11.4% YoY · +6.0% QoQ
- Net income
- −$16M
- −6.0% YoY · +6.4% QoQ
- Operating margin
- -31.2%
- Gross margin
- 79.1%
- EPS (diluted)
- −$0.26
- −4.0% YoY · +7.1% QoQ
Source: XBRL data from the TREACE MEDICAL CONCEPTS, INC. (TMCI) Q3 2025 10-Q on SEC EDGAR. USD.
TREACE MEDICAL CONCEPTS, INC. Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- Newly added litigation risk triggered by October 2024 and May/August 2025 lawsuits against Stryker and Zimmer Biomet for patent infringement seeking damages and injunctive relief
- Most materially updated financial risk: inclusion of $11.0 million initial stocking distributor sales in 9M 2025, expected not to recur, impacting revenue recognition
- Regulatory and legal risk from ongoing patent infringement lawsuits increasing legal fees by $3.6 million in 9M 2025 compared to 2024
- Operational risk from shifting surgeon preferences to minimally invasive osteotomy procedures reducing flagship Lapiplasty System sales despite overall bunion kit volume growth
- Financial liquidity risk with cash and cash equivalents down to $7.7 million as of September 2025, total debt $54.0 million, but $49.7 million marketable securities available for funding operations
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other TREACE MEDICAL CONCEPTS, INC. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.